Opus Genetics Inc. (IRD) posted a net loss of $0.80 per share for fiscal 2025. The company generated $14.2M in revenue for the year. The clinical-stage ophthalmic biopharmaceutical company focuses on developing therapies for inherited retinal diseases.
Opus Genetics is advancing OPGx-LCA5, currently in Phase 1/2 clinical trial for LCA5-associated IRD, and OPGx-BEST1 for BEST1-associated retinal disease. The company operates in the specialized sector of rare genetic eye disorders.
A detailed analysis of Opus Genetics Inc.’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.